Perioperative pembrolizumab or pembrolizumab + enfortumab vedotin and cystectomy versus cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer: Phase 3 KEYNOTE-905/EV-303 study

Authors :: Matthew D. Galsky
E. Plimack
C. Jia
J.A. Witjes
Neal D. Shore
Andrea Necchi
B. Homet Moreno
Source :: European Urology Open Science. 33:S394
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Cisplatin
medicine.medical_specialty
Bladder cancer
business.industry
Urology
medicine.medical_treatment
Muscle invasive
Enfortumab vedotin
Perioperative
Pembrolizumab
medicine.disease
Cystectomy
medicine
business
medicine.drug

Tools